< Back to previous page
Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 100
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study(2023)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 5536 - + - Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI(2023)
Authors: Vincent Vandecaveye, Elleke Dresen, Els Van Nieuwenhuysen, Thaïs Baert, Frédéric Amant, Toon Van Gorp
Pages: 1890 - 1897 - InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer(2023)
Authors: Els Van Nieuwenhuysen, Ignace Vergote
Pages: S1586 - S1586 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial(2023)
Authors: Els Van Nieuwenhuysen
Pages: S1282 - S1283 - innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator′s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer(2023)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: S1276 - S1277 - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study(2023)
Authors: Els Van Nieuwenhuysen
Pages: S516 - S517 - NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer(2023)
Authors: Els Van Nieuwenhuysen
Pages: 1715 - 1727 - Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer(2023)
Authors: Ignace Vergote, Els Van Nieuwenhuysen, Annouschka Laenen, Toon Van Gorp
Pages: 80 - 88 - PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial(2023)
Authors: Liselore Loverix, Ignace Vergote, Pieter Busschaert, Tom Venken, Bram Boeckx, Hilde Brems, Els Van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, et al.
Pages: 131 - 139 - Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.(2023)
Authors: Els Van Nieuwenhuysen
Pages: 1698 - 1707